{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:37:11Z","timestamp":1792820231775,"version":"4.5.0"},"reference-count":83,"publisher":"Japan Academy","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Proc. Jpn. Acad., Ser. B","Proceedings of the Japan Academy. Ser. B: Physical and Biological Sciences"],"published-print":{"date-parts":[[2027]]},"DOI":"10.2183\/pjab.103.001","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:11:50Z","timestamp":1792620710000},"source":"Crossref","is-referenced-by-count":0,"title":["A new era of GPCR drug discovery: From receptor deorphanization to precision therapeutics"],"prefix":"10.2183","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1630-0537","authenticated-orcid":false,"given":"Hidetoshi","family":"KOMATSU","sequence":"first","affiliation":[{"name":"Therapeutics Accelerator, Innovation Lab, Astellas Pharma Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"993","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1) Fredriksson, R., Lagerstr\u00f6m, M.C., Lundin, L.G. and Schi\u00f6th, H.B. (2003) The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol. Pharmacol. <b>63<\/b>, 1256\u20131272. doi: 10.1124\/mol.63.6.1256.","DOI":"10.1124\/mol.63.6.1256"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2) Pierce, K.L., Premont, R.T. and Lefkowitz, R.J. (2002) Seven-transmembrane receptors. Nat. Rev. Mol. Cell Biol. <b>3<\/b>, 639\u2013650. doi: 10.1038\/nrm908.","DOI":"10.1038\/nrm908"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3) Komatsu, H., Mori, I., Rhee, J.S., Akaike, N. and Ohshima, Y. (1996) Mutations in a cyclic nucleotide-gated channel lead to abnormal thermosensation and chemosensation in C. elegans. Neuron <b>17<\/b>, 707\u2013718. doi: 10.1016\/s0896-6273(00)80202-0.","DOI":"10.1016\/S0896-6273(00)80202-0"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Hauser, A.S., Attwood, M.M., Rask-Andersen, M., Schi\u00f6th, H.B. and Gloriam, D.E. (2017) Trends in GPCR drug discovery: new agents, targets and indications. Nat. Rev. Drug Discov. <b>16<\/b>, 829\u2013842. doi: 10.1038\/nrd.2017.178.","DOI":"10.1038\/nrd.2017.178"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5) Sriram, K. and Insel, P.A. (2018) G protein-coupled receptors as targets for approved drugs: how many targets and how many drugs? Mol. Pharmacol. <b>93<\/b>, 251\u2013258. doi: 10.1124\/mol.117.111062.","DOI":"10.1124\/mol.117.111062"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6) Drucker, D.J. (2018) Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. <b>27<\/b>, 740\u2013756. doi: 10.1016\/j.cmet.2018.03.001.","DOI":"10.1016\/j.cmet.2018.03.001"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Lorente, J.S., Sokolov, A.V., Ferguson, G., Schi\u00f6th, H.B., Hauser, A.S. and Gloriam, D.E. (2025) GPCR drug discovery: new agents, targets and indications. Nat. Rev. Drug Discov. <b>24<\/b>, 458\u2013479. doi: 10.1038\/s41573-025-01139-y.","DOI":"10.1038\/s41573-025-01139-y"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8) Kenakin, T. (2011) Functional selectivity and biased receptor signaling. J. Pharmacol. Exp. Ther. <b>336<\/b>, 296\u2013302. doi: 10.1124\/jpet.110.173948.","DOI":"10.1124\/jpet.110.173948"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Rajagopal, S., Rajagopal, K. and Lefkowitz, R.J. (2010) Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat. Rev. Drug Discov. <b>9<\/b>, 373\u2013386. doi: 10.1038\/nrd3024.","DOI":"10.1038\/nrd3024"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10) Palczewski, K., Kumasaka, T., Hori, T., Behnke, C.A., Motoshima, H., Fox, B.A. et al. (2000) Crystal structure of rhodopsin: a G protein-coupled receptor. Science <b>289<\/b>, 739\u2013745. doi: 10.1126\/science.289.5480.739.","DOI":"10.1126\/science.289.5480.739"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11) Rasmussen, S.G.F., Choi, H.J., Rosenbaum, D.M., Kobilka, T.S., Thian, F.S., Edwards, P.C. et al. (2007) Crystal structure of the human \u03b22 adrenergic G-protein-coupled receptor. Nature <b>450<\/b>, 383\u2013387. doi: 10.1038\/nature06325.","DOI":"10.1038\/nature06325"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12) Rasmussen, S.G.F., DeVree, B.T., Zou, Y., Kruse, A.C., Chung, K.Y., Kobilka, T.S. et al. (2011) Crystal structure of the \u03b22 adrenergic receptor-Gs protein complex. Nature <b>477<\/b>, 549\u2013555. doi: 10.1038\/nature10361.","DOI":"10.1038\/nature10361"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13) Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O. et al. (2021) Highly accurate protein structure prediction with AlphaFold. Nature <b>596<\/b>, 583\u2013589. doi: 10.1038\/s41586-021-03819-2.","DOI":"10.1038\/s41586-021-03819-2"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Schneider, G. (2018) Automating drug discovery. Nat. Rev. Drug Discov. <b>17<\/b>, 97\u2013113. doi: 10.1038\/nrd.2017.232.","DOI":"10.1038\/nrd.2017.232"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G. et al. (2019) Applications of machine learning in drug discovery and development. Nat. Rev. Drug Discov. <b>18<\/b>, 463\u2013477. doi: 10.1038\/s41573-019-0024-5.","DOI":"10.1038\/s41573-019-0024-5"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16) Zhavoronkov, A., Ivanenkov, Y.A., Aliper, A., Veselov, M.S., Aladinskiy, V.A., Aladinskaya, A.V. et al. (2019) Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nat. Biotechnol. <b>37<\/b>, 1038\u20131040. doi: 10.1038\/s41587-019-0224-x.","DOI":"10.1038\/s41587-019-0224-x"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17) Congreve, M., de Graaf, C., Swain, N.A. and Tate, C.G. (2020) Impact of GPCR structures on drug discovery. Cell <b>181<\/b>, 81\u201391. doi: 10.1016\/j.cell.2020.03.003.","DOI":"10.1016\/j.cell.2020.03.003"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18) Garc\u00eda-Nafr\u00eda, J. and Tate, C.G. (2020) Cryo-electron microscopy: moving beyond X-ray crystal structures for drug receptors and drug development. Annu. Rev. Pharmacol. Toxicol. <b>60<\/b>, 51\u201371. doi: 10.1146\/annurev-pharmtox-010919-023545.","DOI":"10.1146\/annurev-pharmtox-010919-023545"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19) Civelli, O., Reinscheid, R.K., Zhang, Y., Wang, Z., Fredriksson, R. and Schi\u00f6th, H.B. (2013) G protein-coupled receptor deorphanizations. Annu. Rev. Pharmacol. Toxicol. <b>53<\/b>, 127\u2013146. doi: 10.1146\/annurev-pharmtox-010611-134548.","DOI":"10.1146\/annurev-pharmtox-010611-134548"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20) Itoh, Y., Kawamata, Y., Harada, M., Kobayashi, M., Fujii, R., Fukusumi, S. et al. (2003) Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature <b>422<\/b>, 173\u2013176. doi: 10.1038\/nature01478.","DOI":"10.1038\/nature01478"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21) Briscoe, C.P., Tadayyon, M., Andrews, J.L., Benson, W.G., Chambers, J.K., Eilert, M.M. et al. (2003) The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J. Biol. Chem. <b>278<\/b>, 11303\u201311311. doi: 10.1074\/jbc.M211495200.","DOI":"10.1074\/jbc.M211495200"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22) Latour, M.G., Alquier, T., Oseid, E., Tremblay, C., Jetton, T.L., Luo, J. et al. (2007) GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo. Diabetes <b>56<\/b>, 1087\u20131094. doi: 10.2337\/db06-1532.","DOI":"10.2337\/db06-1532"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23) Steneberg, P., Rubins, N., Bartoov-Shifman, R., Walker, M.D. and Edlund, H. (2005) The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab. <b>1<\/b>, 245\u2013258. doi: 10.1016\/j.cmet.2005.03.007.","DOI":"10.1016\/j.cmet.2005.03.007"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24) Tsujihata, Y., Ito, R., Suzuki, M., Harada, A., Negoro, N., Yasuma, T. et al. (2011) TAK-875, an orally available G protein-coupled receptor 40\/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. J. Pharmacol. Exp. Ther. <b>339<\/b>, 228\u2013237. doi: 10.1124\/jpet.111.183772.","DOI":"10.1124\/jpet.111.183772"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25) Negoro, N., Sasaki, S., Mikami, S., Ito, M., Suzuki, M., Tsujihata, Y. et al. (2010) Discovery of TAK-875: a potent, selective, and orally bioavailable GPR40 agonist. ACS Med. Chem. Lett. <b>1<\/b>, 290\u2013294. doi: 10.1021\/ml1000855.","DOI":"10.1021\/ml1000855"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26) Burant, C.F., Viswanathan, P., Marcinak, J., Cao, C., Vakilynejad, M., Xie, B. et al. (2012) TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet <b>379<\/b>, 1403\u20131411. doi: 10.1016\/S0140-6736(11)61879-5.","DOI":"10.1016\/S0140-6736(11)61879-5"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27) Kaku, K., Enya, K., Nakaya, R., Ohira, T. and Matsuno, R. (2015) Efficacy and safety of fasiglifam (TAK-875) in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Obes. Metab. <b>17<\/b>, 675\u2013681. doi: 10.1111\/dom.12467.","DOI":"10.1111\/dom.12467"},{"key":"28","doi-asserted-by":"publisher","unstructured":"28) Marcinak, J.F., Cao, C., Vakilynejad, M., Kaspers, S. and Burant, C.F. (2017) Fasiglifam for glycaemic control in people with type 2 diabetes: a phase 3, placebo-controlled study. Diabetes Obes. Metab. <b>19<\/b>, 1714\u20131721. doi: 10.1111\/dom.12988.","DOI":"10.1111\/dom.12988"},{"key":"29","doi-asserted-by":"publisher","unstructured":"29) Marcinak, J.F., Munsaka, M.S., Watkins, P.B., Ohira, T. and Smith, N. (2018) Liver safety of fasiglifam (TAK-875) in patients with type 2 diabetes: review of the global clinical trial experience. Drug Saf. <b>41<\/b>, 625\u2013640. doi: 10.1007\/s40264-018-0642-6.","DOI":"10.1007\/s40264-018-0642-6"},{"key":"30","doi-asserted-by":"publisher","unstructured":"30) Yabuki, C., Komatsu, H., Tsujihata, Y., Maeda, R., Ito, R., Matsuda-Nagasumi, K. et al. (2013) A novel antidiabetic drug, fasiglifam\/TAK-875, acts as an ago-allosteric modulator of FFAR1. PLoS One <b>8<\/b>, e76280. doi: 10.1371\/journal.pone.0076280.","DOI":"10.1371\/journal.pone.0076280"},{"key":"31","doi-asserted-by":"publisher","unstructured":"31) Sakuma, K., Yabuki, C., Maruyama, M., Abiru, A., Komatsu, H., Negoro, N. et al. (2016) Fasiglifam (TAK-875) has dual potentiating mechanisms via G\u03b1q-GPR40\/FFAR1 signaling branches on glucose-dependent insulin secretion. Pharmacol. Res. Perspect. <b>4<\/b>, e00237. doi: 10.1002\/prp2.237.","DOI":"10.1002\/prp2.237"},{"key":"32","doi-asserted-by":"publisher","unstructured":"32) Srivastava, A., Yano, J., Hirozane, Y., Kefala, G., Gruswitz, F., Snell, G. et al. (2014) High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875. Nature <b>513<\/b>, 124\u2013127. doi: 10.1038\/nature13494.","DOI":"10.1038\/nature13494"},{"key":"33","doi-asserted-by":"publisher","unstructured":"33) Lu, J., Byrne, N., Wang, J., Bricogne, G., Brown, F.K., Chobanian, H.R. et al. (2017) Structural basis for the cooperative allosteric activation of the free fatty acid receptor GPR40. Nat. Struct. Mol. Biol. <b>24<\/b>, 570\u2013577. doi: 10.1038\/nsmb.3417.","DOI":"10.1038\/nsmb.3417"},{"key":"34","doi-asserted-by":"publisher","unstructured":"34) Fukusumi, S., Yoshida, H., Fujii, R., Maruyama, M., Komatsu, H., Habata, Y. et al. (2003) A new peptidic ligand and its receptor regulating adrenal function in rats. J. Biol. Chem. <b>278<\/b>, 46387\u201346395. doi: 10.1074\/jbc.M305270200.","DOI":"10.1074\/jbc.M305270200"},{"key":"35","doi-asserted-by":"publisher","unstructured":"35) Shinohara, T., Harada, M., Ogi, K., Maruyama, M., Fujii, R., Tanaka, H. et al. (2004) Identification of a G protein-coupled receptor specifically responsive to beta-alanine. J. Biol. Chem. <b>279<\/b>, 23559\u201323564. doi: 10.1074\/jbc.M314240200.","DOI":"10.1074\/jbc.M314240200"},{"key":"36","doi-asserted-by":"publisher","unstructured":"36) Komatsu, H., Maruyama, M., Yao, S., Shinohara, T., Sakuma, K., Imaichi, S. et al. (2014) Anatomical transcriptome of G protein-coupled receptors leads to the identification of a novel therapeutic candidate GPR52 for psychiatric disorders. PLoS One <b>9<\/b>, e90134. doi: 10.1371\/journal.pone.0090134.","DOI":"10.1371\/journal.pone.0090134"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Komatsu, H. (2015) Novel therapeutic GPCRs for psychiatric disorders. Int. J. Mol. Sci. <b>16<\/b>, 14109\u201314121. doi: 10.3390\/ijms160614109.","DOI":"10.3390\/ijms160614109"},{"key":"38","doi-asserted-by":"publisher","unstructured":"38) Setoh, M., Ishii, N., Kono, M., Miyanohana, Y., Shiraishi, E., Harasawa, T. et al. (2014) Discovery of the first potent and orally available agonist of the orphan G-protein-coupled receptor 52. J. Med. Chem. <b>57<\/b>, 5226\u20135237. doi: 10.1021\/jm5002919.","DOI":"10.1021\/jm5002919"},{"key":"39","doi-asserted-by":"publisher","unstructured":"39) Nishiyama, K., Suzuki, H., Harasawa, T., Suzuki, N., Kurimoto, E., Kawai, T. et al. (2017) FTBMT, a novel and selective GPR52 agonist, demonstrates antipsychotic-like and procognitive effects in rodents. J. Pharmacol. Exp. Ther. <b>363<\/b>, 253\u2013264. doi: 10.1124\/jpet.117.242925.","DOI":"10.1124\/jpet.117.242925"},{"key":"40","unstructured":"40) Nxera Pharma Co., Ltd. (2025) Nxera Pharma to regain full rights to GPR52 agonist program for schizophrenia. Company announcement, 19 December 2025. Available at: https:\/\/ssl4.eir-parts.net\/doc\/4565\/tdnet\/2732901\/00.pdf (accessed 25 August 2026)."},{"key":"41","doi-asserted-by":"publisher","unstructured":"41) Lin, X., Li, M., Wang, N., Wu, Y., Luo, Z., Guo, S. et al. (2020) Structural basis of ligand recognition and self-activation of orphan GPR52. Nature <b>579<\/b>, 152\u2013157. doi: 10.1038\/s41586-020-2019-0.","DOI":"10.1038\/s41586-020-2019-0"},{"key":"42","doi-asserted-by":"crossref","first-page":"e05449","DOI":"10.7554\/eLife.05449","author":"Y. Yao","year":"2015","unstructured":"42) Yao, Y., Cui, X., Al-Ramahi, I., Sun, X., Li, B., Hou, J. et al. (2015) A striatal-enriched intronic GPCR modulates huntingtin levels and toxicity. eLife <b>4<\/b>, e05449. doi: 10.7554\/eLife.05449.","journal-title":"eLife","ISSN":"https:\/\/id.crossref.org\/issn\/2050-084X","issn-type":"print"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Song, H., Li, H., Guo, S., Pan, Y., Fu, Y., Zhou, Z. et al. (2018) Targeting Gpr52 lowers mutant HTT levels and rescues Huntington\u2019s disease-associated phenotypes. Brain <b>141<\/b>, 1782\u20131798. doi: 10.1093\/brain\/awy081.","DOI":"10.1093\/brain\/awy081"},{"key":"44","doi-asserted-by":"publisher","unstructured":"44) Wang, C., Zhang, Y.-F., Guo, S., Zhao, Q., Zeng, Y., Xie, Z. et al. (2021) GPR52 antagonist reduces huntingtin levels and ameliorates Huntington\u2019s disease-related phenotypes. J. Med. Chem. <b>64<\/b>, 941\u2013957. doi: 10.1021\/acs.jmedchem.0c01133.","DOI":"10.1021\/acs.jmedchem.0c01133"},{"key":"45","doi-asserted-by":"publisher","unstructured":"45) Komatsu, H. (2021) Innovative therapeutic approaches for Huntington\u2019s disease: from nucleic acids to GPCR-targeting small molecules. Front. Cell. Neurosci. <b>15<\/b>, 785703. doi: 10.3389\/fncel.2021.785703.","DOI":"10.3389\/fncel.2021.785703"},{"key":"46","doi-asserted-by":"publisher","unstructured":"46) Komatsu, H. (2021) Discovery of the first druggable GPR52 antagonist to treat Huntington\u2019s disease. J. Med. Chem. <b>64<\/b>, 938\u2013940. doi: 10.1021\/acs.jmedchem.0c02235.","DOI":"10.1021\/acs.jmedchem.0c02235"},{"key":"47","doi-asserted-by":"publisher","unstructured":"47) Wootten, D., Christopoulos, A., Marti-Solano, M., Babu, M.M. and Sexton, P.M. (2018) Mechanisms of signaling and biased agonism in G protein-coupled receptors. Nat. Rev. Mol. Cell Biol. <b>19<\/b>, 638\u2013653. doi: 10.1038\/s41580-018-0049-3.","DOI":"10.1038\/s41580-018-0049-3"},{"key":"48","doi-asserted-by":"publisher","unstructured":"48) Eichel, K. and von Zastrow, M. (2018) Subcellular organization of GPCR signaling. Trends Pharmacol. Sci. <b>39<\/b>, 200\u2013208. doi: 10.1016\/j.tips.2017.11.009.","DOI":"10.1016\/j.tips.2017.11.009"},{"key":"49","doi-asserted-by":"publisher","unstructured":"49) Dolph, P.J., Ranganathan, R., Colley, N.J., Hardy, R.W., Socolich, M. and Zuker, C.S. (1993) Arrestin function in inactivation of G protein-coupled receptor rhodopsin in vivo. Science <b>260<\/b>, 1910\u20131916. doi: 10.1126\/science.8316831.","DOI":"10.1126\/science.8316831"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Wootten, D., Christopoulos, A. and Sexton, P.M. (2013) Emerging paradigms in GPCR allostery: implications for drug discovery. Nat. Rev. Drug Discov. <b>12<\/b>, 630\u2013644. doi: 10.1038\/nrd4052.","DOI":"10.1038\/nrd4052"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Komatsu, H., Fukuchi, M. and Habata, Y. (2019) Potential utility of biased GPCR signaling for treatment of psychiatric disorders. Int. J. Mol. Sci. <b>20<\/b>, 3207. doi: 10.3390\/ijms20133207.","DOI":"10.3390\/ijms20133207"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Nobles, K.N., Xiao, K., Ahn, S., Shukla, A.K., Lam, C.M., Rajagopal, S. et al. (2011) Distinct phosphorylation sites on the beta2-adrenergic receptor establish a barcode that encodes differential functions of beta-arrestin. Sci. Signal. <b>4<\/b>, ra51. doi: 10.1126\/scisignal.2001707.","DOI":"10.1126\/scisignal.2001707"},{"key":"53","doi-asserted-by":"publisher","unstructured":"53) Lee, Y., Warne, T., Nehm\u00e9, R., Pandey, S., Dwivedi-Agnihotri, H., Chaturvedi, M. et al. (2020) Molecular basis of beta-arrestin coupling to formoterol-bound beta1-adrenoceptor. Nature <b>583<\/b>, 862\u2013866. doi: 10.1038\/s41586-020-2419-1.","DOI":"10.1038\/s41586-020-2419-1"},{"key":"54","doi-asserted-by":"publisher","unstructured":"54) Irannejad, R., Tomshine, J.C., Tomshine, J.R., Chevalier, M., Mahoney, J.P., Steyaert, J. et al. (2013) Conformational biosensors reveal GPCR signaling from endosomes. Nature <b>495<\/b>, 534\u2013538. doi: 10.1038\/nature12000.","DOI":"10.1038\/nature12000"},{"key":"55","doi-asserted-by":"publisher","unstructured":"55) Anderson, P.J., Xiao, P., Zhong, Y.-N., Kaakati, A.N., Alfonso-DeSouza, J., Patino, A. et al. (2026) \u03b2-Arrestin condensates regulate G-protein-coupled receptor function. Nature <b>655<\/b>, 525\u2013534. doi: 10.1038\/s41586-026-10539-y.","DOI":"10.1038\/s41586-026-10539-y"},{"key":"56","doi-asserted-by":"publisher","unstructured":"56) Yen, Y.-C., Schafer, C.T., Gustavsson, M., Eberle, S.A., Dominik, P.K., Deneka, D. et al. (2022) Structures of atypical chemokine receptor 3 reveal the basis for its promiscuity and signaling bias. Sci. Adv. <b>8<\/b>, eabn8063. doi: 10.1126\/sciadv.abn8063.","DOI":"10.1126\/sciadv.abn8063"},{"key":"57","doi-asserted-by":"publisher","unstructured":"57) DeWire, S.M., Yamashita, D.S., Rominger, D.H., Liu, G., Cowan, C.L., Graczyk, T.M. et al. (2013) A G protein-biased ligand at the mu-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J. Pharmacol. Exp. Ther. <b>344<\/b>, 708\u2013717. doi: 10.1124\/jpet.112.201616.","DOI":"10.1124\/jpet.112.201616"},{"key":"58","doi-asserted-by":"publisher","unstructured":"58) Viscusi, E.R., Skobieranda, F., Soergel, D.G., Cook, E., Burt, D.A. and Singla, N. (2019) APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the \u00b5-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy. J. Pain Res. <b>12<\/b>, 927\u2013943. doi: 10.2147\/JPR.S171013.","DOI":"10.2147\/JPR.S171013"},{"key":"59","doi-asserted-by":"publisher","unstructured":"59) Singla, N.K., Skobieranda, F., Soergel, D.G., Salamea, M., Burt, D.A., Demitrack, M.A. et al. (2019) APOLLO-2: a randomized, placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the \u00b5-opioid receptor, for management of moderate-to-severe acute pain following abdominoplasty. Pain Pract. <b>19<\/b>, 715\u2013731. doi: 10.1111\/papr.12801.","DOI":"10.1111\/papr.12801"},{"key":"60","doi-asserted-by":"publisher","unstructured":"60) Fukuchi, M., Tabuchi, A., Kuwana, Y., Watanabe, S., Inoue, M., Takasaki, I. et al. (2015) Neuromodulatory effect of G\u03b1s- or G\u03b1q-coupled G-protein-coupled receptor on NMDA receptor selectively activates the NMDA receptor\/calcineurin\/CRTC1\/CREB-regulated transcriptional pathway to induce brain-derived neurotrophic factor expression in neurons. J. Neurosci. <b>35<\/b>, 5606\u20135624. doi: 10.1523\/JNEUROSCI.3650-14.2015.","DOI":"10.1523\/JNEUROSCI.3650-14.2015"},{"key":"61","doi-asserted-by":"publisher","unstructured":"61) Sakuma, K., Komatsu, H., Maruyama, M., Imaichi, S., Habata, Y. and Mori, M. (2015) Temporal and spatial transcriptional fingerprints by antipsychotic or propsychotic drugs in mouse brain. PLoS One <b>10<\/b>, e0118510. doi: 10.1371\/journal.pone.0118510.","DOI":"10.1371\/journal.pone.0118510"},{"key":"62","doi-asserted-by":"publisher","unstructured":"62) Liang, Y.-L., Khoshouei, M., Radjainia, M., Zhang, Y., Glukhova, A., Tarrasch, J. et al. (2017) Phase-plate cryo-EM structure of a class B GPCR-G-protein complex. Nature <b>546<\/b>, 118\u2013123. doi: 10.1038\/nature22327.","DOI":"10.1038\/nature22327"},{"key":"63","doi-asserted-by":"publisher","unstructured":"63) Weis, W.I. and Kobilka, B.K. (2018) The molecular basis of G protein-coupled receptor activation. Annu. Rev. Biochem. <b>87<\/b>, 897\u2013919. doi: 10.1146\/annurev-biochem-060614-033910.","DOI":"10.1146\/annurev-biochem-060614-033910"},{"key":"64","doi-asserted-by":"publisher","unstructured":"64) Wootten, D., Miller, L.J., Koole, C., Christopoulos, A. and Sexton, P.M. (2017) Allostery and biased agonism at class B G protein-coupled receptors. Chem. Rev. <b>117<\/b>, 111\u2013138. doi: 10.1021\/acs.chemrev.6b00049.","DOI":"10.1021\/acs.chemrev.6b00049"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65) Ballesteros, J.A. and Weinstein, H. (1995) Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. <i>In<\/i> Methods in Neurosciences, Vol. 25 (ed. Sealfon, S.C.). Academic Press, San Diego, pp. 366\u2013428. doi: 10.1016\/S1043-9471(05)80049-7.","DOI":"10.1016\/S1043-9471(05)80049-7"},{"key":"66","doi-asserted-by":"publisher","unstructured":"66) Zhang, X., Belousoff, M.J., Zhao, P., Kooistra, A.J., Truong, T.T., Ang, S.Y. et al. (2020) Differential GLP-1R binding and activation by peptide and non-peptide agonists. Mol. Cell <b>80<\/b>, 485\u2013500.e7. doi: 10.1016\/j.molcel.2020.09.020.","DOI":"10.1016\/j.molcel.2020.09.020"},{"key":"67","doi-asserted-by":"publisher","unstructured":"67) Zhang, X., Belousoff, M.J., Liang, Y.L., Danev, R., Sexton, P.M. and Wootten, D. (2021) Structure and dynamics of semaglutide- and taspoglutide-bound GLP-1R-Gs complexes. Cell Rep. <b>36<\/b>, 109374. doi: 10.1016\/j.celrep.2021.109374.","DOI":"10.1016\/j.celrep.2021.109374"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68) Kawai, T., Sun, B., Yoshino, H., Feng, D., Suzuki, Y., Fukazawa, M. et al. (2020) Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proc. Natl. Acad. Sci. U.S.A. <b>117<\/b>, 29959\u201329967. doi: 10.1073\/pnas.2014879117.","DOI":"10.1073\/pnas.2014879117"},{"key":"69","doi-asserted-by":"publisher","unstructured":"69) Griffith, D.A., Edmonds, D.J., Fortin, J.-P., Kalgutkar, A.S., Kuzmiski, J.B., Loria, P.M. et al. (2022) A small-molecule oral agonist of the human glucagon-like peptide-1 receptor. J. Med. Chem. <b>65<\/b>, 8208\u20138226. doi: 10.1021\/acs.jmedchem.1c01856.","DOI":"10.1021\/acs.jmedchem.1c01856"},{"key":"70","doi-asserted-by":"publisher","unstructured":"70) Wharton, S., Blevins, T., Connery, L., Rosenstock, J., Raha, S., Liu, R. et al. (2023) Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N. Engl. J. Med. <b>389<\/b>, 877\u2013888. doi: 10.1056\/NEJMoa2302392.","DOI":"10.1056\/NEJMoa2302392"},{"key":"71","doi-asserted-by":"publisher","unstructured":"71) Buckeridge, C., Cobain, S., Bays, H.E., Matsuoka, O., Fukushima, Y., Halstead, P. et al. (2025) Efficacy and safety of danuglipron (PF-06882961) in adults with obesity: A randomized, placebo-controlled, dose-ranging phase 2b study. Diabetes Obes. Metab. <b>27<\/b>, 4915\u20134926. doi: 10.1111\/dom.16534.","DOI":"10.1111\/dom.16534"},{"key":"72","doi-asserted-by":"publisher","unstructured":"72) Watson, J.L., Juergens, D., Bennett, N.R., Trippe, B.L., Yim, J., Eisenach, H.E. et al. (2023) De novo design of protein structure and function with RFdiffusion. Nature <b>620<\/b>, 1089\u20131100. doi: 10.1038\/s41586-023-06415-8.","DOI":"10.1038\/s41586-023-06415-8"},{"key":"73","doi-asserted-by":"publisher","unstructured":"73) Abramson, J., Adler, J., Dunger, J., Evans, R., Green, T., Pritzel, A. et al. (2024) Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature <b>630<\/b>, 493\u2013500. doi: 10.1038\/s41586-024-07487-w.","DOI":"10.1038\/s41586-024-07487-w"},{"key":"74","doi-asserted-by":"publisher","unstructured":"74) Ballante, F., Kooistra, A.J., Kampen, S., de Graaf, C. and Carlsson, J. (2021) Structure-based virtual screening for ligands of G protein-coupled receptors: what can molecular docking do for you? Pharmacol. Rev. <b>73<\/b>, 527\u2013565. doi: 10.1124\/pharmrev.120.000246.","DOI":"10.1124\/pharmrev.120.000246"},{"key":"75","doi-asserted-by":"publisher","unstructured":"75) Stein, R.M., Kang, H.J., McCorvy, J.D., Glatfelter, G.C., Jones, A.J., Che, T. et al. (2020) Virtual discovery of melatonin receptor ligands to modulate circadian rhythms. Nature <b>579<\/b>, 609\u2013614. doi: 10.1038\/s41586-020-2027-0.","DOI":"10.1038\/s41586-020-2027-0"},{"key":"76","doi-asserted-by":"publisher","unstructured":"76) Lyu, J., Wang, S., Balius, T.E., Singh, I., Levit, A., Moroz, Y.S. et al. (2019) Ultra-large library docking for discovering new chemotypes. Nature <b>566<\/b>, 224\u2013229. doi: 10.1038\/s41586-019-0917-9.","DOI":"10.1038\/s41586-019-0917-9"},{"key":"77","doi-asserted-by":"publisher","unstructured":"77) Sterling, T. and Irwin, J.J. (2015) ZINC 15\u2014Ligand discovery for everyone. J. Chem. Inf. Model. <b>55<\/b>, 2324\u20132337. doi: 10.1021\/acs.jcim.5b00559.","DOI":"10.1021\/acs.jcim.5b00559"},{"key":"78","doi-asserted-by":"publisher","unstructured":"78) Cabeza de Vaca, I., Trapkov, B., Shen, L., Vo, D.D., Zhang, X., Yang, Y. et al. (2026) Ultra-large virtual screening unveils potent agonists of the neuromodulatory orphan receptor GPR139. Nat. Commun. <b>17<\/b>, 129. doi: 10.1038\/s41467-025-66845-y.","DOI":"10.1038\/s41467-025-66845-y"},{"key":"79","doi-asserted-by":"publisher","unstructured":"79) Kaplan, A.L., Confair, D.N., Kim, K., Barros-\u00c1lvarez, X., Rodriguiz, R.M., Yang, Y. et al. (2022) Bespoke library docking for 5-HT2A receptor agonists with antidepressant activity. Nature <b>610<\/b>, 582\u2013591. doi: 10.1038\/s41586-022-05258-z.","DOI":"10.1038\/s41586-022-05258-z"},{"key":"80","doi-asserted-by":"publisher","unstructured":"80) Fink, E.A., Xu, J., H\u00fcbner, H., Braz, J.M., Seemann, P., Avet, C. et al. (2022) Structure-based discovery of nonopioid analgesics acting through the \u03b1<sub>2A<\/sub>-adrenergic receptor. Science <b>377<\/b>, eabn7065. doi: 10.1126\/science.abn7065.","DOI":"10.1126\/science.abn7065"},{"key":"81","doi-asserted-by":"publisher","unstructured":"81) Motso, A., Pelcman, B., Kalinovich, A., Kahlous, N.A., Bokhari, M.H., Dehvari, N. et al. (2025) GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity. Cell <b>188<\/b>, 5142\u20135156.e23. doi: 10.1016\/j.cell.2025.05.042.","DOI":"10.1016\/j.cell.2025.05.042"},{"key":"82","doi-asserted-by":"publisher","unstructured":"82) Motso, A., Pelcman, B., Kalinovich, A., Kahlous, N.A., Bokhari, M.H., Dehvari, N. et al. (2025) Correction: GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity. Cell <b>188<\/b>, 5429\u20135431. doi: 10.1016\/j.cell.2025.08.022.","DOI":"10.1016\/j.cell.2025.08.022"},{"key":"83","doi-asserted-by":"publisher","unstructured":"83) Wei, T.T., Chandy, M., Nishiga, M., Zhang, A., Kumar, K.K., Thomas, D. et al. (2022) Cannabinoid receptor 1 antagonist genistein attenuates marijuana-induced vascular inflammation. Cell <b>185<\/b>, 1676\u20131693.e23. doi: 10.1016\/j.cell.2022.04.005.","DOI":"10.1016\/j.cell.2022.04.005"}],"container-title":["Proceedings of the Japan Academy, Series B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/pjab\/advpub\/0\/advpub_pjab.103.001\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:40:44Z","timestamp":1792816844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/pjab\/advpub\/0\/advpub_pjab.103.001\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027]]},"references-count":83,"URL":"https:\/\/doi.org\/10.2183\/pjab.103.001","relation":{},"ISSN":["0386-2208","1349-2896"],"issn-type":[{"value":"0386-2208","type":"print"},{"value":"1349-2896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2027]]},"article-number":"pjab.103.001"}}